Close Menu

Almac

The Craigavon, UK-based company said that it opened the facility in response to an increase in the number of clinical trial-related projects it has commenced with biopharmaceutical companies.

The two companies announced plans to develop a companion diagnostic to predict whether non-squamous non-small cell lung cancer patients can benefit from combination treatment with Alimta and cisplatin based on the thymidylate synthase biomarker.

Almac and Lilly will study a predictive marker for use as a companion diagnostic for a combination therapy.

Austin Tanney, Almac Diagnostics' scientific liaison manager, said this week that any markers identified at the University of Miami will be in the hands of the researchers, but should panels with diagnostics potential be discovered, Almac will consult with the university to commercialize them.

The school will use the company's cancer diagnostic microarray to study ethnic differences in breast cancer.

Pages

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.